Posted by Michael Wonder on 19 May 2023
NICE recommends Rinvoq (upadacitinib) as a treatment option for moderately to severely active Crohn’s disease
18 May 2023 - The NICE recommendation is based on data from three Phase 3 clinical trials demonstrating upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response at week 12 and week 52 (p<0.001 vs placebo).
AbbVie today announced that NICE has issued positive final draft guidance recommending Rinvoq (upadacitinib) as an option for treating moderately to severely active Crohn’s disease in adults when the condition has not responded well enough or has lost response to a previous biological treatment, or when a previous biological treatment was not tolerated, or when tumour necrosis factor-alpha inhibitors are contra-indicated.
